Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab

Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab

Immune checkpoint inhibitors (ICIs) for treatment of metastatic melanoma (MM) offer lasting overall survival (OS) benefit in a subset of patients. However, outcomes remain poor for non-responders. Clinical predictors of long-term survival remain elusive. We utilized the Alberta Immunotherapy Databas...

Full description

Bibliographic Details
Main Authors: Siddhartha Goutam, Igor Stukalin, Benjamin Ewanchuk, Michael Sander, Philip Q. Ding, Daniel E. Meyers, Daniel Heng, Winson Y. Cheung, Tina Cheng
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Current Oncology
Subjects:
immunotherapy
metastatic melanoma
immune checkpoint inhibitors
survival
long-term survival
short-term survival
Online Access:https://www.mdpi.com/1718-7729/29/10/608

Internet

https://www.mdpi.com/1718-7729/29/10/608

Similar Items